FEATURED

COVID 19 Articles

Trending COVID 19 News

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results for a cancer vaccine developed by Merck and Moderna using technology from Personalis, which Tempus is acquiring.

read more